Jemperli (Dostarlimab) 500mg/10ml vial • GSK • Turkey pharmacy vs Baku retail vs quote on request — cold-chain delivery

Jemperli (dostarlimab) is for patients with confirmed dMMR/MSI-H status. Without that test result a supply enquiry cannot be completed, so attach it in the first message.
Recurrent or advanced endometrial cancer, and dMMR/MSI-H solid tumours after prior systemic therapy.
Concentrate for infusion, 500 mg/10 mL vial, stored at 2-8°C. First four doses three-weekly, then 1000 mg every six weeks.
It is a comparatively new agent with thin regional stock, and the switch from the three-weekly to the six-weekly schedule needs vial planning in two stages.